16,840 Shares in Quest Diagnostics Incorporated $DGX Purchased by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd purchased a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX) in the 4th quarter, Holdings Channel reports. The institutional investor purchased 16,840 shares of the medical research company’s stock, valued at approximately $2,922,000. Quest Diagnostics accounts for approximately 0.7% of Dynamic Technology Lab Private Ltd’s investment portfolio, making the stock its 7th largest holding.

Several other large investors have also recently added to or reduced their stakes in the company. Korea Investment CORP raised its holdings in Quest Diagnostics by 50.3% during the fourth quarter. Korea Investment CORP now owns 44,829 shares of the medical research company’s stock worth $7,779,000 after purchasing an additional 15,000 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in Quest Diagnostics during the fourth quarter worth about $5,189,000. Wealthspire Advisors LLC raised its holdings in Quest Diagnostics by 30.6% during the fourth quarter. Wealthspire Advisors LLC now owns 3,865 shares of the medical research company’s stock worth $671,000 after purchasing an additional 905 shares in the last quarter. Summit Financial LLC raised its holdings in Quest Diagnostics by 10.0% during the fourth quarter. Summit Financial LLC now owns 2,189 shares of the medical research company’s stock worth $380,000 after purchasing an additional 199 shares in the last quarter. Finally, FineMark National Bank & Trust raised its holdings in Quest Diagnostics by 0.7% during the fourth quarter. FineMark National Bank & Trust now owns 25,419 shares of the medical research company’s stock worth $4,411,000 after purchasing an additional 166 shares in the last quarter. 88.06% of the stock is owned by hedge funds and other institutional investors.

Quest Diagnostics Trading Down 0.6%

Shares of Quest Diagnostics stock opened at $202.62 on Friday. Quest Diagnostics Incorporated has a 12-month low of $164.65 and a 12-month high of $213.50. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.67. The stock has a market cap of $22.43 billion, a PE ratio of 22.39, a price-to-earnings-growth ratio of 2.43 and a beta of 0.59. The company has a 50-day moving average of $194.99 and a two-hundred day moving average of $191.86.

Quest Diagnostics (NYSE:DGX) last issued its earnings results on Tuesday, April 21st. The medical research company reported $2.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.37 by $0.13. Quest Diagnostics had a net margin of 9.07% and a return on equity of 15.60%. The company had revenue of $2.90 billion during the quarter, compared to analysts’ expectations of $2.83 billion. During the same period last year, the company posted $1.94 earnings per share. The firm’s quarterly revenue was up 9.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. On average, research analysts anticipate that Quest Diagnostics Incorporated will post 10.72 EPS for the current fiscal year.

Quest Diagnostics Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 22nd. Shareholders of record on Wednesday, July 8th will be issued a $0.86 dividend. The ex-dividend date of this dividend is Wednesday, July 8th. This represents a $3.44 dividend on an annualized basis and a yield of 1.7%. Quest Diagnostics’s dividend payout ratio (DPR) is 38.01%.

Insider Transactions at Quest Diagnostics

In other Quest Diagnostics news, CEO J. E. Davis sold 10,000 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $194.14, for a total value of $1,941,400.00. Following the completion of the transaction, the chief executive officer directly owned 132,423 shares of the company’s stock, valued at approximately $25,708,601.22. This trade represents a 7.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the completion of the transaction, the senior vice president directly owned 13,510 shares of the company’s stock, valued at approximately $2,702,000. This trade represents a 37.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.88% of the company’s stock.

Wall Street Analyst Weigh In

DGX has been the subject of several analyst reports. UBS Group increased their price target on shares of Quest Diagnostics from $210.00 to $220.00 and gave the stock a “neutral” rating in a report on Wednesday, April 22nd. Weiss Ratings raised shares of Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a report on Tuesday. Jefferies Financial Group reissued a “buy” rating and set a $225.00 price target on shares of Quest Diagnostics in a report on Tuesday, April 21st. Wall Street Zen cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Saturday, May 30th. Finally, Robert W. Baird increased their target price on shares of Quest Diagnostics from $224.00 to $229.00 and gave the company a “neutral” rating in a report on Wednesday, April 22nd. Seven investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, Quest Diagnostics presently has a consensus rating of “Moderate Buy” and a consensus target price of $216.58.

Quest Diagnostics Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.